Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at acute lymphoblastic leukaemia that has not responded to treatment or has come back (Alcantara Study)
This trial looked at a drug called blinatumomab for acute lymphoblastic leukaemia that has come back after or continued to get worse during treatment.
This study was for people with acute lymphoblastic leukaemia (ALL) that has the
More about this trial
- how well blinatumomab works for acute lymphoblastic leukaemia that has the Philadelphia chromosome
- more about the side effects
Summary of results
- whose ALL had either gone away completely or had gone away but their blood test results hadn’t fully recovered
- 14 had no signs of leukaemia in their blood tests - this is called minimal residual disease
- 2 had some signs of leukaemia in their blood tests
- high temperatures (fever)
- an increased risk of infection (neutropenia) with a fever
- infection (neutropenia) with a fever
- tiredness and breathlessness (anaemia)
- 3 people developed mild problems from a side effect called cytokine release syndrome – this causes fever, sickness, headache, rash, rapid heartbeat, low blood pressure, and trouble breathing
- 3 people had problems with their
central nervous systemincluding 1 person who had difficulty speaking. Their treatment was stopped for a short time and this side effect got better.
How to join a clinical trial
Dr Adele Fielding